Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Easywell Biomedicals's interest expense for the
three
months ended in Dec. 2025 was NT$ -4.9 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-22.5 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Easywell Biomedicals's Operating Income for the
three
months ended in Dec. 2025 was NT$ -30.1 Mil. Easywell Biomedicals's Interest Expense for the
three
months ended in Dec. 2025 was NT$ -4.9 Mil.
Easywell Biomedicals did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Easywell Biomedicals's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as
Easywell Biomedicals did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Easywell Biomedicals Interest Expense Historical Data
* Premium members only.
The historical data trend for Easywell Biomedicals's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-22.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Expense of NT$-22.5 Mil mean?
Easywell Biomedicals (ROCO:1799) has a Interest Expense of NT$-22.5 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Easywell Biomedicals and its competitors.
Is Easywell Biomedicals' Interest Expense too high?
Easywell Biomedicals' current Interest Expense is NT$-22.5 Mil. Overall, Easywell Biomedicals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Easywell Biomedicals' Interest Expense compare to ZTS and UTHR?
Easywell Biomedicals' Interest Expense of NT$-22.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Easywell Biomedicals and its competitors. Easywell Biomedicals's current Interest Expense is NT$-22.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easywell Biomedicals stock overvalued right now?
Based on GuruFocus' analysis, Easywell Biomedicals (ROCO:1799) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$75.62, compared to a current price of NT$35.75 — trading 52.7% below its estimated fair value. The current Interest Expense is NT$-22.5 Mil. Easywell Biomedicals' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Easywell Biomedicals (ROCO:1799), the current Interest Expense is NT$-22.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Easywell Biomedicals (ROCO:1799) Overvalued in 2026?
Based on GuruFocus' analysis, Easywell Biomedicals stock appears to be undervalued.
The current stock price of NT$35.75 is trading 52.7% below its estimated GF Value™ of NT$75.62.
GuruFocus considers Easywell Biomedicals to be Significantly Undervalued.
Key valuation signals for ROCO:1799:
Interest Expense: NT$-22.5 Mil
GF Value™: NT$75.62 vs. price of NT$35.75 (52.7% below fair value)
No single metric tells the full story. See the ROCO:1799 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients, generic drugs, and new drugs. It focuses on complex generics, new drug delivery platforms, and regenerative medicines, with cGMP. The company's segments include the Drug Development segment and the Other segment. Geographically, the company operates in America, China, and Taiwan regions.
55GF Score
Get the complete analysis for ROCO:1799
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1799 has been successfully added to your 
